Navigation Links
Pharsight Expands Strategic Consulting Services Team

Pharsight Strengthens US Team with Addition of Jonathan Monteleone and

Herbert Struemper

MOUNTAIN VIEW, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software and strategic services for optimizing clinical drug development, today announced that it has hired Jonathan Monteleone, M.S., and Herbert Struemper, Ph.D., as senior associate scientists in the Company's Strategic Consulting Services group. Both Mr. Monteleone and Dr. Struemper will be based in the United States out of Pharsight's Cary, North Carolina office.

"The addition of two new scientists is another key step as we continue to grow our world class consulting team at Pharsight," said Shawn O'Connor, president, chief executive officer and chairman of Pharsight. "Dr. Struemper and Mr. Monteleone both have a unique combination of deep technical expertise and knowledge of drug development decision-making processes that will be of significant value to our consulting team. We look forward to their contributions that we believe will further enhance the services that we can provide to our clients."

Dr. Struemper comes to Pharsight from Entelos Incorporated, where he led in silico research and development projects in rheumatoid arthritis, obesity and diabetes. He has broad experience in biomarker identification and evaluation, drug-disease modeling, and clinical trial design and simulation. Dr. Struemper holds a Ph.D. in Electrical Engineering from the University of Maryland in College Park. He also completed a postdoctoral research fellowship at the California Institute of Technology in Pasadena, California, where he designed motion control algorithms for nonlinear robotic systems. Dr. Struemper holds four life sciences patents, including two patents on methods for computer modeling of human physiological processes.

Mr. Monteleone joins Pharsight from Dov Pharmaceuticals, where he focused on population PK/PD modeling of small molecules in the areas of analgesia and depression. Mr. Monteleone also served as a lecturer in the Department of Pharmacology at the University of Auckland in New Zealand, where he provided instruction on clinical pharmacokinetics concepts and modeling tools, including Pharsight's WinNonlin(R). Mr. Monteleone holds an M.S. in Toxicology from the University of Arizona and has completed coursework for his Ph.D. in Pharmacology and Clinical Pharmacology from the University of Auckland. Mr. Monteleone has authored or co-authored several original research articles in the area of clinical trial design and simulation-based design optimization.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at

Registered Trademarks and Trademarks

Pharsight(R) is a registered trademark of Pharsight Corporation. All other brand and product names are trademarks or registered trademarks of their respective holders.

SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. WARF expands license agreement with Advanced Cell Technology
2. Verizon expands broadband service in Wisconsin
3. Bandwidth provider expands in Milwaukee
4. Wisconsins biodiesel network expands
5. Quad/Graphics expands reach in western states
6. University of South Florida expands GE Healthcare relationship
7. Metavante expands healthcare payments division
8. Fiserv expands services to health plan market
9. Bone Care expands patent protection of core drug offering
10. SBC and AT&T merger expands global reach for Wisconsin businesses
11. Expetec expands IT staff services in Wisconsin
Post Your Comments:
(Date:11/24/2015)... 2015  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... president and chief executive officer, will present at the 27 ... New York City . The presentation will ... 2015 at 9:30 a.m. EST. and ... at least 15 minutes prior to the presentation to allow ...
(Date:11/23/2015)... CHICAGO , Nov. 24, 2015 Women with ... screening CT exams face a higher risk of lung cancer ... being presented next week at the annual meeting of the ... --> --> Lung ... are classified as solid or subsolid based on their appearance ...
(Date:11/23/2015)... VA (PRWEB) , ... November 23, 2015 , ... Noblis, ... McCarthy , former Director, Plans and Programs, National Geospatial Intelligence Agency (NGA), has joined ... us with an incredibly distinguished career in the intelligence community and the private sector,” ...
(Date:11/23/2015)... 2015  CryoLife, Inc. (NYSE: CRY ), a leading ... vascular surgery, announced today that it will participate in the ... Wednesday, December 2, 2015 at The New York Palace Hotel ... Pat Mackin , President and Chief Executive Officer. ... --> A live webcast of the Company,s ...
Breaking Biology Technology:
(Date:10/29/2015)... 2015 NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... a leading marketplace to discover and buy innovative ... wallet on StackSocial for this holiday season.   ... "Company"), a biometric authentication company focused on the ...
(Date:10/26/2015)... India , October 26, 2015 ... --> adds ... 2015 to 2021 as well as ... 2015-2019 research reports to its collection ... . --> ...
(Date:10/22/2015)... BEDFORD, Mass., Oct. 22, 2015  Aware, Inc. (NASDAQ: AWRE ... financial results for its third quarter ended September 30, 2015.  ... third quarter of 2015 was $4.0 million, a decrease of 33% ... income in the third quarter of 2015 was $2.2 million, or ... per diluted share, in the same period a year ago.  ...
Breaking Biology News(10 mins):